Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Choi SH;Choi SH; Bosetti F
  • Source:
    Aging [Aging (Albany NY)] 2009 Feb 11; Vol. 1 (2), pp. 234-44. Date of Electronic Publication: 2009 Feb 11.
  • Publication Type:
    Journal Article; Research Support, N.I.H., Intramural
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Impact Journals, LLC Country of Publication: United States NLM ID: 101508617 Publication Model: Electronic Cited Medium: Internet ISSN: 1945-4589 (Electronic) Linking ISSN: 19454589 NLM ISO Abbreviation: Aging (Albany NY) Subsets: MEDLINE
    • Publication Information:
      Original Publication: Albany, NY : Impact Journals, LLC
    • Subject Terms:
      Amyloid beta-Peptides/*pharmacology ; Brain Diseases/*chemically induced ; Cyclooxygenase 1/*genetics ; Cyclooxygenase 1/*metabolism ; Inflammation/*chemically induced ; Peptide Fragments/*toxicity; Amyloid beta-Peptides/toxicity ; Animals ; Brain Diseases/genetics ; Hippocampus/pathology ; Inflammation/genetics ; Mice ; Mice, Knockout ; Neuroglia ; Oxidative Stress
    • Abstract:
      Several independent epidemiological studies indicate that chronic use of non-steroidal anti-inflammatory drugs can reduce the risk of developing Alzheimer's disease (AD), supporting the inflammatory cascade hypothesis. Although the first clinical trial with indomethacin, a preferential cyclooxygenase (COX)-1 inhibitor, showed beneficial effects, subsequent large clinical trials, mostly using COX-2 inhibitors, failed to show any beneficial effect in AD patients with mild to severe cognitive impairment. These combined data suggest that either an early treatment is crucial to stop the mechanisms underlying the disease before the onset of the symptoms, or that preferential COX-1 inhibition, rather than COX-2, is beneficial. Therefore, a full understanding of the physiological, pathological, and/or neuroprotective role of COX isoforms may help to develop better therapeutic strategies for the prevention or treatment of AD. In this study, we examined the effect of COX-1 genetic deletion on the inflammatory response and neurodegeneration induced by beta-amyloid. beta-amyloid (Abeta(1-42)) was centrally injected in the lateral ventricle of COX-1-deficient (COX-1(-/-)) and their respective wild-type (WT) mice. In COX-1(-/-) mice, Abeta(1-42)-induced inflammatory response and neuronal damage were attenuated compared to WT mice, as shown by Fluoro-Jade B and nitrotyrosine staining. These results indicate that inhibition of COX-1 activity may be valid therapeutic strategy to reduce brain inflammatory response and neurodegeneration.
    • Comments:
      Comment in: Aging (Albany NY). 2009 Apr;1(4):350-3. (PMID: 20157521)
    • References:
      J Neurosci Res. 1999 Jun 15;56(6):565-70. (PMID: 10374811)
      Brain Res. 2002 Oct 4;951(2):218-26. (PMID: 12270500)
      Brain Res. 1996 Jan 15;706(2):181-93. (PMID: 8822355)
      Neuropsychopharmacology. 2005 Jun;30(6):1204-15. (PMID: 15742005)
      Brain Pathol. 1999 Jan;9(1):133-46. (PMID: 9989456)
      Biochim Biophys Acta. 1994 Nov 16;1209(1):130-9. (PMID: 7947975)
      Neurology. 2008 Jun 10;70(24):2291-8. (PMID: 18509093)
      J Neurosci. 2005 Apr 20;25(16):4082-90. (PMID: 15843610)
      Curr Pharm Des. 2008;14(14):1419-27. (PMID: 18537664)
      Neurology. 2000 Jun 13;54(11):2066-71. (PMID: 10851364)
      Pharmacol Ther. 2000 Nov;88(2):93-113. (PMID: 11150591)
      Neuroreport. 2003 Nov 14;14(16):2099-103. (PMID: 14600505)
      Ann N Y Acad Sci. 1999;893:314-20. (PMID: 10672257)
      Neurology. 2008 May 6;70(19):1672-7. (PMID: 18458226)
      J Neurosci. 1997 Apr 15;17(8):2653-7. (PMID: 9092586)
      J Neurosci. 1998 Oct 15;18(20):8126-32. (PMID: 9763459)
      Neurology. 1995 Aug;45(8):1441-5. (PMID: 7644037)
      Genome Biol. 2007;8(1):R14. (PMID: 17266762)
      J Clin Invest. 2003 Aug;112(3):440-9. (PMID: 12897211)
      Neurology. 1997 Mar;48(3):626-32. (PMID: 9065537)
      Neuropsychopharmacology. 2005 Jun;30(6):1111-20. (PMID: 15688088)
      Behav Brain Res. 2007 Feb 27;177(2):205-13. (PMID: 17194489)
      Behav Brain Res. 2004 Dec 6;155(2):185-96. (PMID: 15364477)
      J Biol Chem. 2004 Jan 9;279(2):1415-21. (PMID: 14578353)
      J Neuroinflammation. 2008 May 19;5:17. (PMID: 18489773)
      Br J Pharmacol. 2001 May;133(1):89-96. (PMID: 11325798)
      Brain Res. 2001 Sep 7;912(2):128-36. (PMID: 11532428)
      Neurosci Lett. 1987 Aug 18;79(1-2):195-200. (PMID: 3670729)
      Brain Res. 1997 Mar 14;751(1):37-46. (PMID: 9098566)
      J Neuropathol Exp Neurol. 1999 Nov;58(11):1135-46. (PMID: 10560656)
      J Neurosci. 2007 May 16;27(20):5394-404. (PMID: 17507561)
      J Neurochem. 2004 Jan;88(2):337-48. (PMID: 14690522)
      Nat Med. 2005 May;11(5):545-50. (PMID: 15834426)
      J Neurol Neurosurg Psychiatry. 2006 Jan;77(1):85-8. (PMID: 15944180)
      Brain Res. 1999 Jan 2;815(1):1-10. (PMID: 9974116)
      Exp Neurol. 2006 Apr;198(2):552-7. (PMID: 16480717)
      Am J Pathol. 2004 Dec;165(6):2197-206. (PMID: 15579461)
      N Engl J Med. 2001 Nov 22;345(21):1515-21. (PMID: 11794217)
      Nat Rev Neurosci. 2007 Jan;8(1):57-69. (PMID: 17180163)
      Prog Lipid Res. 2001 Jan-Mar;40(1-2):1-94. (PMID: 11137568)
      J Neurosci. 1998 Mar 15;18(6):2161-73. (PMID: 9482801)
      JAMA. 2003 Jun 4;289(21):2819-26. (PMID: 12783912)
      J Med Chem. 2005 Sep 8;48(18):5705-20. (PMID: 16134939)
      Ann Med. 2002;34(7-8):491-500. (PMID: 12553488)
      Neurology. 1993 Aug;43(8):1609-11. (PMID: 8351023)
      J Pharmacol Exp Ther. 2007 Nov;323(2):488-98. (PMID: 17704356)
      J Neurosci. 2002 Mar 15;22(6):2246-54. (PMID: 11896164)
      FASEB J. 2008 May;22(5):1491-501. (PMID: 18162486)
      Neurology. 1996 Aug;47(2):425-32. (PMID: 8757015)
      Cell. 1995 Nov 3;83(3):483-92. (PMID: 8521478)
      J Neurochem. 2007 Aug;102(3):577-86. (PMID: 17403135)
      Neurology. 1999 Jul 13;53(1):197-201. (PMID: 10408559)
      Nature. 1996 Aug 22;382(6593):685-91. (PMID: 8751438)
      J Lipid Res. 2005 May;46(5):949-68. (PMID: 15716586)
      Neurology. 2000 Jul 25;55(2):323. (PMID: 10908926)
      Nature. 2004 Jun 24;429(6994):883-91. (PMID: 15190254)
      Neurobiol Aging. 2007 May;28(5):639-47. (PMID: 16697488)
      J Neurochem. 2003 Jun;85(6):1394-401. (PMID: 12787059)
      J Neuropathol Exp Neurol. 2004 Sep;63(9):901-10. (PMID: 15453089)
      Nat Med. 2007 Apr;13(4):432-8. (PMID: 17351623)
      Curr Drug Targets. 2003 Aug;4(6):461-8. (PMID: 12866660)
      Neuroscience. 2003;119(2):399-419. (PMID: 12770555)
      Antioxid Redox Signal. 2006 Nov-Dec;8(11-12):2021-37. (PMID: 17034347)
      Brain Res. 2000 Aug 25;874(2):123-30. (PMID: 10960596)
      Nature. 2008 Jun 12;453(7197):925-9. (PMID: 18548070)
      Acta Neuropathol. 2001 Jan;101(1):2-8. (PMID: 11194936)
      Exp Neurol. 2008 Mar;210(1):164-71. (PMID: 18053988)
      Nature. 2004 Aug 5;430(7000):631-9. (PMID: 15295589)
      Neurology. 2004 Jan 13;62(1):66-71. (PMID: 14718699)
      Brain. 2008 Mar;131(Pt 3):651-64. (PMID: 18292081)
      Nat Med. 1999 Dec;5(12):1403-9. (PMID: 10581083)
      Anal Biochem. 1985 Jul;148(1):59-69. (PMID: 2994521)
      Free Radic Biol Med. 2002 Jun 1;32(11):1050-60. (PMID: 12031889)
    • Grant Information:
      United States Intramural NIH HHS
    • Contributed Indexing:
      Keywords: cyclooxygenase; microglia; neuroinflammation; neurotoxicity; oxidative stress
    • Accession Number:
      0 (Amyloid beta-Peptides)
      0 (Peptide Fragments)
      0 (amyloid beta-protein (1-42))
      EC 1.14.99.1 (Cyclooxygenase 1)
    • Publication Date:
      Date Created: 20100217 Date Completed: 20100624 Latest Revision: 20211020
    • Publication Date:
      20231215
    • Accession Number:
      PMC2806008
    • Accession Number:
      10.18632/aging.100021
    • Accession Number:
      20157512